Prognostic effects of oral anti-cancer drugs as adjuvant chemotherapy for 2 years after gastric cancer surgery

Surgery Today

Volumn 42, Issue 8, 2012, Pages 734-740

  Okuyama, Toshiro ^a   Korenaga, Daisuke ^a   Edagawa, Ai ^a   Itoh, Shinji ^a   Oki, Eiji ^b   Kawanaka, Hirofumi ^a   Ikeda, Yasuharu ^a   Kakeji, Yoshihiro ^b   Tateishi, Masahiro ^a   Tsujitani, Shunichi ^b   Takenaka, Kenji ^a   Maehara, Yoshihiko ^b  

^a Fukuoka City Hospital   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Adjuvant chemotherapy; Gastric cancer; Oral anti cancer drugs; Two years administration

Indexed keywords

GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; UFT;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEUTROPENIA; PIGMENTATION; POSTOPERATIVE CARE; PROGNOSIS; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SIDE EFFECT; STOMACH CANCER; THROMBOCYTOPENIA;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; GASTRECTOMY; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; OXONIC ACID; PROGNOSIS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TEGAFUR; TREATMENT OUTCOME; URACIL;

EID: 84863984619     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-012-0129-5     Document Type: Article

References (24)

1. Maehara Y, Sugimachi K, Akagi M, Kakegawa T, Shimazu H, Tomita M. Early postoperative chemotherapy following noncurative resection for patients with advanced gastric cancer. Br J Cancer. 1992;65:413-6.
2. Nakajima T, Nashimoto A, Kitamura M, Kito T, Iwanaga T, Okabayashi K, et al. Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Lancet. 1999;354:273-7.
3. Macdonald J, Smalley SR, Benedetti J, Hundahl SA, Norman C, Estes NC, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725-30.
4. Costanzo FD, Gasperoni S, Manzione L, Bisagni G, Labianca R, Bravi S, et al. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer. 2008;100:388-98.
5. Nakajima T, Kinoshita T, Nashimoto A, Sairenji M, Yamaguchi T, Sakamoto J, et al. Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg. 2007;94:1468-76.
6. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, ACTS-GC Group, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2008;357:1810-20.
7. Hermans J, Bonenkamp JJ, Boon MC, Bunt AM, Ohyama S, Sasako M, et al. Adjuvant therapy after curative resection for gastric cancer : meta-analysis of randomized trials. J clin oncology. 1993;11:1441-7.
8. Pignon JP, Ducreux M. P Rougier. Meta-analysis of adjuvant chemotherapy in gastric cancer: a critical reappraisal. J clin oncol. 1994;12:877-8.
9. Mari E, Floriani I, Tinazzi A, Buda A, Belfiglio M, Valentini M, et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials: A study of the GISCAD. Ann Oncol. 2000;11:837-43.
10. Oba K. Efficacy of adjuvant chemotherapy using tegafur-based regimen for curatively resected gastric cancer: update of a metaanalysis. Int J Clin Oncol. 2009;14:85-9.
11. Fujii M, Kochi M, Takayama T. Recent advances in chemotherapy for advanced gastric cancer in Japan. Surg Today. 2010;40:295-300.
12. Maehara Y, Baba H, Sugimachi K. Adjuvant chemotherapy for gastric cancer: a comprehensive review. Gastric Cancer. 2001;4:175-84.
13. Kodama Y, Kano T, Tamada R, Kumashiro R, Okamura T, Inokuchi K. Combined effect of prophylactic lymphadenectomy and long term combination chemotherapy for curatively resected carcinoma of the stomach. Surg Today. 1982;12:244-8.
14. Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma, 2nd English Edition. Gastric Cancer 1998; 1:10-24.
15. Ringborg U. Adjuvant chemotherapy-a discussion of some basic principles. Acta Oncol. 1991;30:251-3.
16. Tannock I. Adjuvant chemotherapy-basic science. The basic science of oncology. 2004. p. 356-7.
17. Epstein RJ. Maintenance therapy to suppress micrometastasis: the new challenge for adjuvant cancer treatment. Clin Cancer Res. 2005;11:5337-41.
18. Hanaue H, Kurosawa T, Kitano Y, Miyakawa S, Nemoto A, et al. Anticancer drug distribution in lymph and blood during adjuvant chemotherapy after surgery for gastric carcinoma. A study with a combined preparation of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil. Cancer. 1987;59:1571-6.
19. Sugimachi K, Maehara Y, Ogawa M, Kakegawa T, Tomita M. Dose intensity of uracil and tegafur in postoperative chemotherapy for patients with poorly differentiated gastric cancer. Cancer Chemother Pharmacol. 1997;40:233-8.
20. Kaibara N, Soejima K, Nakamura T, Inokuchi K. Postoperative long term cancer chemotherapy for advanced gastric cancer. Surg Today. 1976;6:54-9.
21. Okudaira Y, Sugimachi K, Inokuchi K, Kai H, Kuwano H, Matsuura H. Postoperative long term immunochemotherapy for esophageal carcinoma-5 year survival. Surg Today. 1982;12: 249-56.
22. Maehara Y. S-1 in gastric cancer: a comprehensive review. Gastric Cancer. 2003;6:2-8.
23. Japanese Gastric Cancer Association. Gastric cancer treatment guidelines. 3rd edn. Japan: Japanese Gastric Cancer Association; 2010. p. 26-27 (in Japanese).
24. Tanaka F. UFT (Tegafur and Uracil) as Postoperative Adjuvant Chemotherapy for Solid Tumors (Carcinoma of the Lung, Stomach, Colon/Rectum, and Breast): Clinical Evidence, Mechanism of Action, and Future Direction. Surg Today. 2007;37: 923-43.